About: Impact of decreasing cerebrospinal fluid enterovirus PCR turnaround time on costs and management of children with suspected enterovirus meningitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of decreasing cerebrospinal fluid enterovirus PCR turnaround time on costs and management of children with suspected enterovirus meningitis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Impact of decreasing cerebrospinal fluid enterovirus PCR turnaround time on costs and management of children with suspected enterovirus meningitis
Creator	Dendukuri, Nandini Papenburg, Jesse Yansouni, Cedric Alghounaim, Mohammad Beltempo, Marc Caya, Chelsea Cho, Mingi
Source	Medline; PMC
abstract	To estimate the impact of implementing in-hospital enterovirus (EV) polymerase chain reaction (PCR) testing of cerebrospinal fluid (CSF) with same-day turn-around-time (TAT) on length-of-stay (LOS), antibiotic use and on cost per patient with suspected EV meningitis, compared with testing at an outside reference laboratory. A model-based analysis using a retrospective cohort of all hospitalized children with CSF EV PCR testing done between November 2013 and 2017. The primary outcome measured was the potential date of discharge if the EV PCR result had been available on the same day. Patients with positive EV PCR were considered for potential earlier discharge once clinically stable with no reason for hospitalization other than intravenous antibiotics. Descriptive statistics and cost-sensitivity analyses were performed. CSF EV PCR testing was done on 153 patients, of which 44 (29%) had a positive result. Median test TAT was 5.3 days (IQR 3.9–7.6). Median hospital LOS was 5 days (IQR 3–12). Most (86%) patients received intravenous antibiotics with mean duration of 5.72 ± 6.51 days. No patients with positive EV PCR had a serious bacterial infection. We found that same-day test TAT would reduce LOS and duration of intravenous antibiotics by 0.50 days (95%CI 0.33–0.68) and 0.67 days (95%CI 0.42–0.91), respectively. Same-day test TAT was associated with a cost reduction of 342.83CAD (95%CI 178.14–517.00) per patient with suspected EV meningitis. Compared with sending specimens to a reference laboratory, performing CSF EV PCR in-hospital with same-day TAT was associated with decreased LOS, antibiotic therapy, and cost per patient.
has issue date	2020-01-13(xsd:dateTime)
bibo:doi	10.1007/s10096-019-03799-2
bibo:pmid	31933018
has license	no-cc
sha1sum (hex)	7dea1c8e9419b7698b127cf8c9ae52b3d8fadd8d
schema:url	https://doi.org/10.1007/s10096-019-03799-2
resource representing a document's title	Impact of decreasing cerebrospinal fluid enterovirus PCR turnaround time on costs and management of children with suspected enterovirus meningitis
has PubMed Central identifier	PMC7087931
has PubMed identifier	31933018
schema:publication	Eur J Clin Microbiol Infect Dis
resource representing a document's body	covid:7dea1c8e9419b7698b127cf8c9ae52b3d8fadd8d#body_text
is schema:about of	named entity '2013' named entity 'days' named entity 'estimate' named entity 'reference' named entity 'Most' named entity 'CSF' named entity 'laboratory' named entity 'management' named entity '3.9' named entity 'POLYMERASE CHAIN REACTION' named entity 'AVAILABLE' named entity 'SUSPECTED' named entity 'RESULT' named entity 'MODEL' named entity 'OF-' named entity 'REDUCTION' named entity 'LENGTH' named entity '2886' named entity '5.3' named entity 'ENTEROVIRUS' named entity 'FOUND' named entity '178' named entity 'CONSIDERED' named entity 'EARLIER' named entity 'INTRAVENOUS' named entity 'REFERENCE LABORATORY' named entity 'reference' named entity 'potential' named entity 'therapy' named entity 'cost reduction' named entity 'Patients' named entity 'intravenous antibiotics' named entity 'suspected' named entity 'costs' named entity 'intravenous antibiotics' named entity 'IQR' named entity 'IQR' named entity 'antibiotic therapy' named entity 'PCR' named entity 'hospitalized' named entity 'laboratory facilities' named entity 'nucleic acid' named entity 'antimicrobial therapy' named entity 'descriptive statistics' named entity 'cell count' named entity 'confidence intervals' named entity 'Canada' named entity 'CSF pleocytosis' named entity 'intravenous' named entity 'PCR' named entity 'in-patient' named entity 'intravenous' named entity 'PCR' named entity '95% CI' named entity 'PCR testing' named entity 'intravenous' named entity 'bacterial meningitis' named entity 'CAD' named entity 'LOS' named entity 'PCR' named entity 'Indirect costs' named entity 'CAD' named entity 'LOS' named entity 'CAD' named entity 'etiological agent' named entity 'CSF pleocytosis' named entity 'PCR testing' named entity 'break-even point' named entity 'CSF pleocytosis' named entity 'TATs' named entity 'MUHC' named entity 'PCR' named entity 'seizures' named entity 'Quebec' named entity 'intravenous'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software